Received Jun 1, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 4 | Z014116 | IM / RA |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 4 | Z014116 | — |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 1 | — | — |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 2 | — | — |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 3 | — | — |
No symptoms were reported. / No additional AE; patient received first three doses on 10/22/1996, 12/31/1996 and third dose on 6/11/1997. Caller stated patient was then given a fourth dose on 3/16/2026.; This spontaneous report was received from a Nurse and refers to a 29-year-old patient of unknown gender. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On 22-Oct-1996, the patient was vaccinated with Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB), Suspension for injection, dose number 1 (lot # and expiration date were not reported) for prophylaxis. On 31-Dec-1996 and on 11-Jun-1997, the second and the third doses of Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) were administered, respectively. On 16-Mar-2026, the patient was inadvertently vaccinated with Hepatitis B Vaccine (Recombinant) Suspension for injection (valid lot #Z014116, expiration date: 14-Jul-2028) dose number 4 for prophylaxis (extra dose administered). No symptoms were reported/ no additional AE (no adverse event). Lot # is being requested and will be submitted if received.